Depression
RECOVER trial suggests vagus nerve stimulation benefits some patients with severe treatment-resistant depression for at least two years
由 AI 报道 AI 生成的图像 事实核查
An implanted device that stimulates the vagus nerve was associated with sustained improvements in symptoms, functioning and quality of life among adults with long-standing, treatment-resistant major depression, according to researchers reporting two-year follow-up data from the ongoing RECOVER study led by Washington University School of Medicine in St. Louis.
Researchers at the University of Victoria have discovered that the protein Reelin could help repair leaky gut caused by chronic stress and alleviate depression symptoms. A single injection restored Reelin levels in preclinical models, showing antidepressant effects. The findings highlight the gut-brain connection in mental health.
由 AI 报道
An international meta-analysis with nearly 24,000 elderly reveals that emotional support reduces depressive symptoms in old age more than practical daily help. The research, published in the American Journal of Epidemiology, analyzed data from 11 studies in various countries, including Brazil. Experts emphasize the importance of affective bonds for elderly mental health.
Neuroscientists from Columbia University and McGill University have discovered that high levels of the stress-related protein SGK1 are associated with depression and suicidal behavior in people who experienced childhood adversity. This finding suggests potential for new antidepressants targeting SGK1, particularly for those resistant to current treatments. The research highlights how early trauma alters brain chemistry differently from other forms of depression.
由 AI 报道
Researchers at McGill University and the Douglas Institute have pinpointed two types of brain cells altered in people with depression. Using advanced genomic analysis on post-mortem brain tissue, they found genetic disruptions in excitatory neurons and microglia. The findings, published in Nature Genetics, could lead to more targeted treatments for the condition affecting over 264 million people worldwide.